Person:
BOZYİĞİT, CENGİZ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

BOZYİĞİT

First Name

CENGİZ

Name

Filters

2019 - 201912020 - 20221
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Relationship with excessive daytime sleepiness and serum substance P levels in OSAS patients and the effect of PAP treatment
    (Springer Japan, 2019-07-01) Güçlu, Özge Aydın; Ursavaş, Ahmet; Kasapoğlu, Fikret; Özarda, Yeşim; Bozyiğit, Cengiz; Ocakoğlu, Gökhan; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; KASAPOĞLU, FİKRET; ÖZARDA, YEŞİM; BOZYİĞİT, CENGİZ; OCAKOĞLU, GÖKHAN; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun Boğaz Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-1005-3205; 0000-0003-2215-6973; 0000-0002-1114-6051; 0000-0002-9027-1132; AAI-3877-2021; AAI-3169-2021; AAH-5180-2021; AAL-8873-2021; HLG-6346-2023; AAG-8744-2021; AAG-9930-2019; AAE-1623-2022
    Obstructive sleep apnea syndrome (OSAS) is a commonly seen disorder characterized by repeated episodes of upper airway obstruction during sleep leading to intermittent hypoxemia or arousal. We aim to evaluate the effects of positive airway pressure (PAP) treatment on daytime sleepiness and serum Substance P (SP) levels in OSAS patients. Seventy-one consecutive patients with newly diagnosed OSAS and 19 non-apneic control subjects were enrolled to the study. PAP treatment indicated subjects were re-evaluated after 3 months of treatment. Morning SP levels of OSAS patients and Epworth sleepiness scale (ESS) were assessed at the beginning and then after 3 months of PAP treatment. Of the patients 71 (78.9%) were male and 19 (21.1%) were female, with a median age of 45 [20-62]. The levels of SP in the OSAS group were significantly lower than the snorer group and a significant correlation was not found between serum levels of SP and ESS. SP levels were negatively correlated with AHI. The baseline SP median was 336.1pg/mL [121.6-536.1], while the 3rd month SP median was 213.1pg/mL [103.5-727.6]. Serum SP values were found to have significantly decreased at 3months (p<0.0001). Statistically significant correlation was not found between percentage of ESS change and the percentage of SP change. It can be assumed that the SP level is reduced as part of the compensation mechanism in OSAS cases and supporting this mechanism, the PAP therapy further reduces the SP value by relieving the cases from apnea and the intermittent hypoxia burden.
  • No Thumbnail Available
    Publication
    Serum mindin, nephrin and podocalyxin levels in patients with type 1 diabetes: Are these new markers to detect the development of nephropathy?
    (Galenos Publ House, 2022-08-01) Sambel, Irmak Tanal; Eren, Erdal; EREN, ERDAL; SARANDÖL, EMRE; Bozyiğit, Cengiz; BOZYİĞİT, CENGİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; 0000-0002-1684-1053; 0000-0003-2215-6973; 0000-0002-2593-7196; JPK-3909-2023
    Introduction: Type 1 diabetes mellitus (DM) is a chronic disease that develops as a result of absolute insulin deficiency. DM is accompanied by chronic complications which are associated with a high risk of morbidity and mortality. In the present study, we aimed to understand whether serum mindin, nephrin (NPHS1) and podocalyxin (PODXL) are useful biomarkers in the determination of nephropathy in patients with type 1 DM and to understand any correlation between serum mindin, PODXL, nephrin levels and hemoglobin A1c (HbA1c) levels and 24 hour urinary albumin excretion of patients. We investigated serum PODXL, nephrin and mindin levels in pediatric patients with type 1 DM.Materials and Methods: Forty patients with type 1 DM along with controls, all in the pubertal stage, were included in the study. Serum mindin, nephrin and PODXL levels were measured using commercial ELISA kits. In the DM group, the mean age, gender distribution, follow-up time, and HbA1c levels were evaluated.Results: There was no significant difference in the serum mindin levels between the DM and control groups (p=0.053). When the serum nephrin levels were compared between the two groups, the nephrin levels were significantly lower in the DM group (p=0.016). The serum PODXL levels of the DM group were significantly lower when compared to the control group (p=0.014).Conclusion: We found that the blood levels of nephrin, PODXL were decreased in the DM group. These markers can be excreted in urine and may be sensitive markers for DM. This is the first study in the literature to evaluate PODXL, mindin, nephrin biomarkers in pediatric patients with type 1 DM.